Vascular Nanotransfer Technologies Poised for Breakthrough Interventional Applications with Its Next-Generation Drug-Coated-Balloon (DCB) Platform Technology

AUBURNDALE, Mass. -- (BUSINESS WIRE) -- Vascular Nanotransfer Technologies (“VNT”) (www.vnanotech.com), an emerging medical technology company that has developed an innovative platform resulting in a proprietary Drug Coated Balloon (“DCB”), is featured in today’s issue of The Sentinel, published by OneMedPlace.

Click here for the complete story.

About Vascular Nanotransfer Technologies (“VNT”)
Privately held VNT, based in Auburndale, Mass., is developing Drug-Coated Balloons (DCB) that are designed to be a more precise delivery vehicle and be the standard treatment of choice for vascular atherosclerosis as well as non-vascular applications.

CAUTION: VNT’s DCBs are not approved for sale.